Esaxerenone - Daiichi Sankyo

Drug Profile

Esaxerenone - Daiichi Sankyo

Alternative Names: CS-3150; XL-550

Latest Information Update: 20 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Developer Daiichi Sankyo Company; Exelixis
  • Class Antihyperglycaemics; Antihypertensives; Pyrroles; Small molecules; Sulfones
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hypertension
  • Phase III Diabetic nephropathies; Essential hypertension; Hyperaldosteronism
  • No development reported Cardiovascular disorders; Heart failure

Most Recent Events

  • 08 Jun 2018 Efficacy and adverse events data from the phase III ESAX-HTN trial in Essential hypertension presented 28th European Meeting on Hypertension and Cardiovascular Protection (ESH-2018)
  • 27 Feb 2018 Preregistration for Hypertension in Japan (PO)
  • 24 Sep 2017 Daiichi Sankyo announces intention to submit regulatory application to Japanese regulatory authority for Essential hypertension in the first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top